⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601393 | 1.00 | — | — | |
| SCHEMBL4920092 | 1.00 | — | — | |
| SCHEMBL2831670 | 0.97 | — | — | |
| SCHEMBL13292040 | 0.97 | — | — | |
| SCHEMBL2831669 | 0.97 | — | — | |
| SCHEMBL9545869 | 0.83 | — | — | |
| SCHEMBL28381006 | 0.80 | ALDH1A1 (0.33) | — | |
| SCHEMBL12551207 | 0.75 | RAB9A (0.33) | — | |
| SCHEMBL1447597 | 0.73 | — | — | |
| SCHEMBL5553 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
| US-6319946-B1 | BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| EP-0361157-B1 | Phenyl pyridines | HOFFMANN LA ROCHE (CH) | 1994-03-02 | — | — | EP | disclosed |
| US-5284956-A | Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines | HOFFMANN-LA ROCHE INC. (US) | 1994-02-08 | — | — | US | disclosed |
| US-5081136-A | 1,2,3-TRIAZOLE COMPOUNDS ACTIVE AS INHIBITORS OF THE ENZYME HMG-COA REDUCTASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZAMBON GROUP S.P.A. (IT) | 1992-01-14 | — | — | US | disclosed |
| EP-0433842-A2 | 1,2,3-Triazole derivatives active as inhibitors of the enzyme HMG-COA reductase and pharmaceutical compositions containing them | ZAMBON GROUP S.p.A. (IT) | 1991-06-26 | — | — | EP | disclosed |
| EP-0242716-B1 | LIQUID-CRYSTALLINE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-03-20 | — | — | EP | disclosed |
| EP-0361157-A1 | Phenyl pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1990-04-04 | — | — | EP | disclosed |
| US-4898455-A | Pyridine liquid crystalline compounds | HOFFMANN-LA ROCHE INC. (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0242716-A1 | Liquid-crystalline pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-10-28 | — | — | EP | disclosed |